"Descrizione" by AColumn (9309 pt) | 2023-Sep-11 09:48 |
Evaluation | N. Experts | Evaluation | N. Experts |
---|---|---|---|
1 | 6 | ||
2 | 7 | ||
3 | 8 | ||
4 | 9 | ||
5 | 10 |
Lansoprazole is a chemical compound, a benzimidazole sulphoxide derivative is a member of the pyridines and benzimidazoles.
It occurs as a fine, white powder.
What it is used for and where
Take only under medical supervision
It is one of the proton pump inhibitors (omeprazole, pantoprazole, esomeprazole, rabeprazole and ilaprazole) as a potent inhibitor of gastric acid secretion and is widely used for the treatment of gastroesophageal reflux, dyspepsia and peptic ulcer (1).
It's one of the well tolerated drugs and since it has a certain sensitivity to acids, it is normally administered in the form of capsules containing granules coated with enteric substances to prevent gastric decomposition and to increase bioavailability.
Due to its anti-inflammatory properties, it inhibits the induction of various inflammatory mediators, thus preventing acute liver damage (2).
Lansoprazole supplementation (50 mg/kgBW) for 4 weeks produced significant decreases in the renal cyst and an improvement in renal function through the reduction of plasma creatinine and blood urea nitrogen (3).
Like all drugs it can cause side effects. Always consult your doctor.
Typical commercial product characteristics Lansoprazole
Appearance | White powder |
Boiling Point | 555.8±60.0 °C at 760 mmHg |
Melting Point | 178-182°C dec. |
Flash Point | 289.9±32.9°C |
Density | 1.5±0.1 g/cm3 |
Loss on drying | ≤2.0% |
Heavy metals | ≤10 ppm |
Water | ≤1.0% |
Sulphated ash | ≤0.5%/g |
Residue on ignition | ≤0.1% |
Safety |
Synonyms:
References________________________________________
(1) Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)]. Inatomi N, Nitta K, Sakurai Y. Nihon Yakurigaku Zasshi. 2008 Feb;131(2):149-56.
(2) The Proton Pump Inhibitor Lansoprazole Has Hepatoprotective Effects in In Vitro and In Vivo Rat Models of Acute Liver Injury. Nakatake R, Hishikawa H, Kotsuka M, Ishizaki M, Matsui K, Nishizawa M, Yoshizawa K, Kaibori M, Okumura T. Dig Dis Sci. 2019 Oct;64(10):2854-2866. doi: 10.1007/s10620-019-05622-6.
(3) Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion. Nantavishit J, Chatsudthipong V, Soodvilai S. Biochem Pharmacol. 2018 Aug;154:175-182. doi: 10.1016/j.bcp.2018.05.005.
Evaluate |